Renal Cancer – Topic Hub

Explore Grand Rounds in Urology talks categorized Renal Cancer.

Sort by Disease State / Sort by Treatment and Special Topics

Sort by Disease State

TitleSpeakerDisease StateSubstageRisk-categoryHistologyLine-of-therapy
Highlights of AUA, GU ASCO, ASCO, and ASTROHanan Goldberg, MD, MSc2026Bladder Cancer, Prostate Cancer, Renal Cancer
Caution from a Urologic Oncologist on Adjuvant Therapy in Renal Cell CarcinomaE. David Crawford, MD2026Renal Cancer
Is There Still a Role for Cytoreductive Nephrectomy?Jodi K. Maranchie, MD, FACS2026Renal Cancer, MetastaticStage IVIntermediate, HighClear Cell, Collecting DuctInitial
Priming the Immune Landscape in RCC with Vascular Normalizing StrategiesJodi K. Maranchie, MD, FACS2026Renal CancerT1, CISHigh
Pro: Adjuvant Therapy: Debating the Role of Adjuvant Therapy for AllRana R. McKay, MD, FASCO2025
Current Options for RCC with Divergent HistologyBradley McGregor, MD, FASCO2025
The Evolving Role of Adjuvant Immunotherapy in RCCSusan F. Slovin, MD, PhD2025
Frontline Treatment Strategies: Personalized Approaches to Advanced RCC ManagementRana R. McKay, MD, FASCO2025
Later-Line Treatment Options: Sequencing Therapies for Optimal Patient OutcomesYu-Wei Chen, MD, MS2025
Debating the Role of Adjuvant Therapy for AllBradley McGregor, MD, FASCO2025
Localized Renal Cell Carcinoma: Surgical & Non-Surgical ApproachesMichael A. Daneshvar, MD, MS2025
Management of Advanced Renal Cancer: Current StatusRobert Dreicer, MD, MS, MACP, FASCO2025
Salvage Partial and Radical Nephrectomy: Principles and StrategiesRichard E. Link, MD, PhD2025
Update on Adjuvant Therapy for Advanced Renal Cell CarcinomaJennifer M. Taylor, MD, MPH2025
Post-ESMO 2025 Highlights: Kidney Cancer StudiesAndrew W. Hahn, MD2025
Cryoablation of Small Renal Masses: Tips for the APPMasters M. Richards, MD2025
Kidney Cancer Journal | Volume 9, June 2025Kidney Cancer Journal2025
Kidney Cancer Journal | Volume 9, January - December 2025Kidney Cancer Journal2024
From Trauma to Oncological Minimally Invasive Urology a Career Shaped by Inspiring MentorsFernando J. Kim, MD, MBA, FACS2025
Management Of High-Risk Renal Cell Carcinoma Update 2024Benjamin R. Lee, MD2024
Alternative Access Approaches for Less-invasive Nephron-sparing SurgeryRichard E. Link, MD, PhD2024
Novel Imaging for Renal Mass CharacterizationMohamad E. Allaf, MD2024
Management of Small Renal Tumors: A Guidelines Based ApproachMohamad E. Allaf, MD2024
Renal Ablation Technologies – Impact on the Treatment of Small Renal MassesThomas W. Jarrett, MD2024
Updates on the Latest Classifications of Urothelial CancersFrancisco G. La Rosa, MD2024
Kidney Preservation for Upper-Tract Urothelial Carcinoma: Current State and Future DirectionsJay D. Raman, MD2023
Role of Neoadjuvant/Adjuvant Immunotherapy in Patients with Localized Renal Cell Carcinoma: The PROSPER Trial and BeyondMohamad E. Allaf, MD2024
Kidney Cancer Journal | Volume 8, January - December 2024Kidney Cancer Journal2024
Diagnosing Renal Masses: Do Advanced Imaging Techniques and Biomarkers Play an Important Role?Justin J. Badal, MD2023
Competing Risks for Small Renal MassesJeremy Slawin, MD, MBA2023
PCNL: Obtaining Access and Preventing InfectionBenjamin K. Canales, MD, MPH2023
Kidney Cancer Journal | Volume 7, Issue 1Kidney Cancer Journal2023
Robotic-Assisted or Open Partial Nephrectomy in Intermediate/High-Complexity RCCArnulf Stenzl, MD2023
Kidney Cancer Journal | Volume 6, Issue 4Kidney Cancer Journal2022
Mutliparametric MRI for Solid Masses: Accurate Detection of Clear Cell Renal Cell Carcinoma to Direct Patient CareJeffrey A Cadeddu, MD2022
Kidney Cancer Journal | Volume 6, Issue 3Kidney Cancer Journal2022
Kidney Tumor Ablation in 2022: Optimal OutcomesJeffrey A Cadeddu, MD2022
Kidney Cancer Journal | Volume 6, Issue 2Kidney Cancer Journal2022
Kidney Cancer Journal | Volume 6, Issue 1Kidney Cancer Journal2022
Nephron-Sparing Renal Surgery: A Deeper Dive Into How Local Recurrence Issues Alter Preoperative and Postoperative Decision-MakingRichard E. Link, MD, PhD2022
Is Open Partial Nephrectomy Still an Option for Challenging Renal Masses?Michael A. Brooks, MD2021
Kidney Cancer Journal | Volume 5, Issue 4Kidney Cancer Journal2021
Updates in Treatment of Renal Cell CarcinomaRobert Dreicer, MD, MS, MACP, FASCO2021
Retroperitoneoscopic Kidney Surgery Tips and TricksQian Zhang, MD, PhD2021
Renal Mass and Localized Renal Cancer: Active Surveillance and Follow-up After InterventionSteven C. Campbell, MD, PhD2021
Renal Mass and Localized Renal Cancer Evaluation and ManagementSteven C. Campbell, MD, PhD2021
Kidney Cancer Journal | Volume 5, Issue 3Kidney Cancer Journal2021
Kidney Cancer Journal | Volume 5, Issue 2Kidney Cancer Journal2021
Endoscopic Challenges in the Renal Transplant PatientWesley A. Mayer, MD2021
Kidney Cancer Journal | Volume 5, Issue 1Kidney Cancer Journal2021
Can You Drive a Stick? Prevention and Management of Bleeding During Minimally Invasive Renal SurgeryRichard E. Link, MD, PhD2021
Kidney Cancer Journal | Volume 4, Issue 4Kidney Cancer Journal2020
Kidney Cancer Journal | Volume 4, Issue S1Kidney Cancer Journal2020
Kidney Cancer Journal | Volume 4, Issue 3Kidney Cancer Journal2020
Renorrhaphy Techniques During Partial Nephrectomy: Technical Points and Functional OutcomesPierluigi Bove, MD2020
Kidney Cancer Journal | Volume 4, Issue 2Kidney Cancer Journal2020
Kidney Cancer Journal | Volume 4, Issue 1Kidney Cancer Journal2020
Guidelines Based Management of Localized and Locally Advanced RCCRobert G. Uzzo, MD, MBA, FACS2019
Kidney Cancer Journal | Volume 3, Issue 4Kidney Cancer Journal2019
Case-Based Tumor Board: Confronting Management Controversies in Renal Cell CarcinomaMichael A. Brooks, MD2019
Renal Autotransplant, When All Else FailsMichael S. Davis, MD, MBA, MHA, FACS2019
Kidney Cancer Journal | Volume 3, Issue 3Kidney Cancer Journal2019
Kidney Cancer Journal | Volume 3, Issue 2Kidney Cancer Journal2019
Recent Advances for Renal Cell Carcinoma: A 2018 ReviewErik P. Castle, MD, FACS2018
Adjuvant Therapy in High Risk Renal Cell CarcinomaAlan H. Bryce, MD2018
Kidney Cancer Journal | Volume 3, Issue 1Kidney Cancer Journal2019
Autosomal Dominant Polycystic Kidney Disease: Medical Considerations and Operative Magic TricksRichard E. Link, MD, PhD2018
The Bottom Line: Practical Application of Clinical Trial Data to Advanced Renal Cell CarcinomaWesley A. Mayer, MD2018
Why Should a Clinician Care About 3D Printing, VR Simulators and Genetically Engineered Animal Models for Kidney Cancer?Richard E. Link, MD, PhD2018
Fancy New Tools and Techniques Applied to Challenges in Robotic Partial NephrectomySamit D. Soni, MD2018
Controversies in Renal Cell Carcinoma: Adjuvant TKIs and Clinical Trial UpdatesDaniel P. Petrylak, MD2018
Kidney Cancer Journal | Volume 2, Issue 2Kidney Cancer Journal2018
Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?Riccardo Autorino, MD, PhD, FEBU2018
MRI Fusion BiopsyPeter G. Schulam, MD, PhD2018
Adverse Pathologic Characteristics in the Small Renal MassPeter G. Schulam, MD, PhD2018
Nephron Sparing Surgery for Large Renal Tumors: Always, Sometimes, or Never?Riccardo Autorino, MD, PhD, FEBU2018
Kidney Cancer Journal | Volume 2, Issue 1Kidney Cancer Journal2018
Active Surveillance for von Hippel-Lindau-Related Renal Tumors using Size-Based Risk Stratification: Longterm ResultsKidney Cancer Journal2017
Variations in treatment patterns for metastatic renal cell carcinoma (mRCC) between developing and developed countriesKidney Cancer Journal2017
Validation of the Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal CancerKidney Cancer Journal2017
Updated Results From a Phase I Study of Nivolumab in Combination With Sunitinib or Pazopanib in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyKidney Cancer Journal2017
Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyKidney Cancer Journal2017
Treatment patterns among patients with metastatic renal cell carcinoma receiving systemic therapies in US real-world settings between 2006 and 2017Kidney Cancer Journal2017
Treatment of metastatic renal cell carcinoma with the mushroom toxin orellanineKidney Cancer Journal2017
TiNiVo: A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell CarcinomaKidney Cancer Journal2017
Three-Year Efficacy and Safety Update From the Phase III CheckMate 025 Study of Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC)Kidney Cancer Journal2017
The impact of bone metastasis location in the clinical outcome of patients with metastatic renal cell carcinoma (mRCC): an analysis from the Latin American Renal Cancer Group (LARCG)Kidney Cancer Journal2017
The association of sarcopenia and tumor aggressiveness in clear cell renal cell carcinomaKidney Cancer Journal2017
The Association between Insurance Status and Survival in Metastatic Renal Cell Carcinoma in the United StatesKidney Cancer Journal2017
Systemic therapy for oligo-progressive, metastatic renal cell carcinoma (mRCC) treated with stereotactic radiosurgery (SBRT): to switch or not to switch?Kidney Cancer Journal2017
Second-Line Treatment of Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-AnalysisKidney Cancer Journal2017
Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trialKidney Cancer Journal2017
Safety of Nivolumab in Patients With Clear Cell (CC) or Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC): Results From the Phase IIIb/IV CheckMate 374 StudyKidney Cancer Journal2017
Rheumatologic adverse events in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitorsKidney Cancer Journal2017
Results of lymph node dissection for locally advanced and metastatic renal cell carcinomaKidney Cancer Journal2017
Quality-adjusted survival of nivolumab vs. everolimus in patients with previously treated advanced renal cell carcinoma (aRCC): a Q-TWiST analysisKidney Cancer Journal2017
PT2977, a Novel HIF-2a Antagonist, Affords Potent Anti-Tumor Activity and Remodels the Immunosuppressive Tumor Microenvironment in Clear Cell Renal Cell CancerKidney Cancer Journal2017
Productivity, Satisfaction, and HealthRelated Quality of Life in Advanced Renal Cell Carcinoma Patients Receiving 2 or More Lines of Treatment: Results from a United Kingdom (UK) chart reviewKidney Cancer Journal2017
Predictive genomic markers of response to VEGF targeted therapy (TT) in metastatic renal cell carcinoma (mRCC): Role of VHL and TP53 mutation, and FLT1 germline variantKidney Cancer Journal2017
Plasma glycosaminoglycan scores in early stage renal cell carcinomaKidney Cancer Journal2017
Physician Treatment Selection in the Prospective Metastatic Renal Cell Cancer (MaRCC) RegistryKidney Cancer Journal2017
Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysisKidney Cancer Journal2017
Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI)Kidney Cancer Journal2017
Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitorsKidney Cancer Journal2017
Immune Cell Infiltration within Differing Renal Cell Carcinoma Primary Histologies: Preliminary ReportKidney Cancer Journal2017
IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell CarcinomaKidney Cancer Journal2017
Germline Mutations in CancerSusceptibility Genes in Patients with Advanced Renal Cell CarcinomaKidney Cancer Journal2017
Genomic Heterogeneity and the Small Renal MassKidney Cancer Journal2017
Estimating the Social Value Generated by Immunotherapy for Renal Cell Carcinoma PatientsKidney Cancer Journal2017
Effects of pazopanib (PAZ) and sunitinib (SUN) dose modifi cation on safety and effi cacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZKidney Cancer Journal2017
Do CT perfusion measures differ in primary renal tumors versus metastatic lesions in patients receiving treatment for advanced renal cell carcinoma?Kidney Cancer Journal2017
Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective ExperienceKidney Cancer Journal2017
DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo controlled trial.Kidney Cancer Journal2017
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell CarcinomaKidney Cancer Journal2017
Clinical outcomes of patients treated with local therapies with oligometastatic renal cell carcinoma (mRCC).Kidney Cancer Journal2017
Clinical outcome of patients with metastatic Renal Cell Carcinoma (mRCC) progressing on front-line combination regimens that include checkpoint inhibitorsKidney Cancer Journal2017
Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell CarcinomaKidney Cancer Journal2017
Checkpoint Inhibitors in the Management of Renal Cell Carcinoma with Sarcomatoid FeaturesKidney Cancer Journal2017
Characterization of Twitter-based dialogue related to renal cell carcinoma (RCC)Kidney Cancer Journal2017
Axitinib and Cabozantinib in the treatment of sunitinib-refractory patients with metastatic renal cell carcinoma (mRCC): Results of matching adjusted indirect treatment comparison (MAIC) analysis of AXIS and METEOR trialsKidney Cancer Journal2017
Association between stool bacteriomic profile and response to sunitinib in metastatic renal cell carcinoma (mRCC)Kidney Cancer Journal2017
Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal cell carcinoma treated with nivolumabKidney Cancer Journal2017
Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trialKidney Cancer Journal2017
A Phase II Study of the Efficacy and Safety of Axitinib (Axi) Given on an Individualized Schedule for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 Inhibitors NCT02579811Kidney Cancer Journal2017
A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinomaKidney Cancer Journal2017
A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma S2Kidney Cancer Journal2017
A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma S1Kidney Cancer Journal2017
A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1Kidney Cancer Journal2017
Adjuvant Sunitinib for High Risk Renal Cell Carcinoma: Not Ready for Prime TimeAlan H. Bryce, MD2017
Recent Advances in Renal Cell CarcinomaErik P. Castle, MD, FACS2017
The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013–2016 from the ClinicalTrials.gov WebsiteKidney Cancer Journal2017
Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell CarcinomaKidney Cancer Journal2017
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic ReviewKidney Cancer Journal2017
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Kidney Cancer Journal2017
Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic ReviewKidney Cancer Journal2017
Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future ChallengesKidney Cancer Journal2017
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best PracticeKidney Cancer Journal2017
Translating Metabolic Reprogramming into New Targets for Kidney CancerKidney Cancer Journal2017